NASDAQ:LIPO Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $0.42 +0.02 (+5.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.39▼$0.4350-Day Range$0.40▼$0.7652-Week Range$0.36▼$2.71Volume51,214 shsAverage Volume48,014 shsMarket Capitalization$3.16 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Lipella Pharmaceuticals alerts: Email Address Lipella Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside381.9% Upside$2.00 Price TargetShort InterestHealthy0.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$7,600 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.97 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLipella Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLipella Pharmaceuticals has received no research coverage in the past 90 days.Read more about Lipella Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.07% of the float of Lipella Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipella Pharmaceuticals has recently decreased by 79.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLipella Pharmaceuticals does not currently pay a dividend.Dividend GrowthLipella Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIPO. Previous Next 2.8 News and Social Media Coverage News SentimentLipella Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lipella Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipella Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,600.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders39.58% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lipella Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioLipella Pharmaceuticals has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lipella Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Lipella Pharmaceuticals Stock (NASDAQ:LIPO)Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Read More LIPO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIPO Stock News HeadlinesMay 31, 2024 | globenewswire.comLipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusMay 29, 2024 | investorplace.comLIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 29, 2024 | globenewswire.comLipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 21, 2024 | globenewswire.comFollowing Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2bMay 13, 2024 | finance.yahoo.comLipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)April 17, 2024 | finance.yahoo.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseApril 17, 2024 | globenewswire.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! April 5, 2024 | globenewswire.comLipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024April 3, 2024 | markets.businessinsider.comLipella Pharmaceuticals Announces Type C Meeting For LP-10 - Quick FactsApril 3, 2024 | globenewswire.comLipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisMarch 7, 2024 | finance.yahoo.comPRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseMarch 5, 2024 | markets.businessinsider.comLipella Pharma's IND Application For LP-410 Gets FDA's ApprovalMarch 3, 2024 | morningstar.comLipella Pharmaceuticals Inc Ordinary Shares LIPOMarch 1, 2024 | finance.yahoo.comLipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)February 20, 2024 | finance.yahoo.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 20, 2024 | globenewswire.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceSee More Headlines Receive LIPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIPO CUSIPN/A CIK1347242 Weblipella.com Phone412-901-0315FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+381.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,620,000.00 Net Margins-991.79% Pretax Margin-991.79% Return on Equity-171.66% Return on Assets-145.43% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$450,000.00 Price / Sales7.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book0.77Miscellaneous Outstanding Shares7,610,000Free Float4,596,000Market Cap$3.16 million OptionableNot Optionable Beta0.57 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jonathan Kaufman M.B.A. (Age 57)Ph.D., Co-Founder, Chairman, CEO, President, Secretary & Treasurer Comp: $204.13kDr. Michael B. Chancellor M.D. (Age 65)Co-Founder, Chief Medical Officer & Director Comp: $195.83kMr. Douglas Johnston CPA (Age 39)Chief Financial Officer Comp: $185kMs. Michele GruberDirector of OperationsKatie JohnstonControllerKey CompetitorsUniverse PharmaceuticalsNYSE:UPCKiora PharmaceuticalsNASDAQ:KPRXAvalo TherapeuticsNASDAQ:AVTXVaxxinityNASDAQ:VAXXChemomab TherapeuticsNASDAQ:CMMBView All CompetitorsInsidersJonathan H KaufmanBought 10,000 shares on 5/14/2024Total: $7,600.00 ($0.76/share)Jonathan H KaufmanBought 30,000 shares on 3/18/2024Total: $23,700.00 ($0.79/share)View All Insider Transactions LIPO Stock Analysis - Frequently Asked Questions How have LIPO shares performed this year? Lipella Pharmaceuticals' stock was trading at $1.02 at the beginning of 2024. Since then, LIPO shares have decreased by 59.3% and is now trading at $0.4150. View the best growth stocks for 2024 here. How were Lipella Pharmaceuticals' earnings last quarter? Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.15 million for the quarter. Lipella Pharmaceuticals had a negative trailing twelve-month return on equity of 171.66% and a negative net margin of 991.79%. When did Lipella Pharmaceuticals IPO? Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering (IPO) on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share. How do I buy shares of Lipella Pharmaceuticals? Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIPO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.